Smart, actionable news trusted by millions.
Delivering exclusive news and sharp analysis on finance and investing—all for free.
JUST FOR FUN
@inconnuuconnu Ferrari ♬ son original – Hugo_thss
Ferrari
Despite new data this week showing inflation has cooled, Powell and the Federal Reserve are still expected to hold off on rate cuts.
The new rules are part of the Basel III reforms that were introduced in 2017 and designed in response to the 2008 financial crisis.
The company on Wednesday joined the ranks of fund managers that have filed for exemptive relief to offer ETF share classes of mutual funds.
In an interview with the Financial Times, Starbucks CEO Brian Niccol said the company is exploring a partial sale of its China business.
The Switch 2 sold 3.5 million units in its first four days, and Nintendo’s targeting 15 million units for this fiscal year.
The private sector took off after traditional banks pulled back from some risky lending following the 2008 financial crisis.
Nearly 70% of Americans said financial uncertainty has made them anxious and depressed, according to a Northwestern Mutual report.
Advisors need to embrace social media, podcasting, and client testimonials if they want to reach Gen Z clients, marketing experts say.
Some 80% of Americans are skeptical of the investment and saving information they find on social media.
Conventional wisdom says being on the S&P 500 is a status symbol that is supposed to come with plenty of benefits.
Could GLP-1 weight loss drugs like Ozempic and changing economic winds really take a bite out of the almighty Big Mac?
Glimpse into the future of technology.
As ChatGPT’s partial outage yesterday goes to show, AI companies are still struggling to scale up to artificial general intelligence.
Vanguard reduced fees on 87 funds earlier this year, and Schwab just lowered costs on ETFs with $66 billion in total assets.
Like the rest of its pre-streaming Hollywood peers, Warner Bros. Discovery finds itself trapped between two eras.
ETFs tracking the performance of weight-loss drugs have largely underperformed since launching in late 2023.